Introduction
Renal cell cancer (RCC) consists of multiple subtypes based on histological classification, and RCC incidence continues to increase, with up to 30% of cases with distant metastases at initial diagnosis (1) . Clear cell RCC (ccRCC), the most common and malignant RCC subtype, comprises around 70% of all RCC tumors (2) . Distinct molecular alterations and different clinical outcomes differentiate the RCC subtypes, indicating multiple mechanisms of RCC pathogenesis (3, 4) .
Patients with localized RCC tumors usually undergo nephrectomy, an often curative treatment. However, treatment options for patients with metastatic disease are limited and do not take into consideration the individual pathophysiological and molecular perturbations among different patients. The main therapeutic approach for metastatic RCC is using high doses of interleukin-2 (IL-2). While this therapy has a relatively low response rate, a small percentage of patients exhibit complete remission upon treatment (5) .
Based on increased elucidation of the molecular mechanisms linked to ccRCC and the high vascularization and angiogenesis associated with ccRCC, several new FDA approved anti-angiogenic therapies have recently entered clinical evaluation for metastatic ccRCC. Current agents demonstrating efficacy include bevacizumab, sunitinib, sorafenib, and pazopanib, which inhibit angiogenic pathways through vascular endothelial growth factor (VEGF) receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and Raf serine/threonine kinase pathways (6) (7) (8) (9) , and mechanistic target of rapamycin (mTOR) pathway inhibitors, temsirolimus and everolimus (10) (11) . Nevertheless, almost all patients eventually fail to respond to any of these therapies and succumb to the disease. The variability in RCC clinical outcome among different patients is likely due to the molecular heterogeneity of RCC, which so Transcriptome analysis of RCC has revealed alterations in gene expression specific for RCC subtypes and linked to outcome (4, 12) . We previously identified specific gene signatures for each RCC subtype, for disease progression and metastasis at time of diagnosis, and reported a distant metastasis gene signature (13) . We also reported a protein signature that accurately predicted IL-2 therapy response in RCC patients (14) . Identification of such gene signatures for RCC has not only provided new insights into the molecular mechanisms and biological pathways involved in RCC development and progression, but has also opened the door for evaluating more targeted approaches to RCC therapy and for exploring the potential of disease gene signatures to predict which drugs may have an impact on the disease.
Transcriptional profiling of several human cancer cell lines treated with bioactive small molecules (primarily FDA-approved drugs) led to the establishment of the Connectivity Map (C-MAP) database (http://www.broadinstitute.org/cmap) of, originally, build 01 (a compendium of 453 genome-wide gene expression profiles for a spectrum of 164 small molecules) and, recently, build 02 (more than 7000 genome-wide expression profiles for 1309 small molecules) which can be exploited to discover functional connections between the drug gene signatures and disease gene signatures (15) . C-MAP analysis involves the ranking of drugs based on the highest inverse correlation with the disease-specific gene signatures, providing a score for each drug. Although transcriptome analysis has provided major breakthrough discoveries in cancer, most of the bioinformatics approaches are based on population or group analysis. Few approaches have taken into account gene expression differences in individual cancer patients. The obvious bottlenecks for any such analysis are the number of variables (ten thousands of genes for each patient) and the inability to apply significance estimating statistical approaches to it. While being aware of the shortcomings of analysis of transcriptome data for individual patients, we have developed a novel Individualized Bioinformatics Analysis (IBA) strategy (Bhasin et al., manuscript in preparation) to personalize gene expression analysis and to incorporate the heterogeneity and individual differences in order to identify gene expression changes, signaling pathway alterations as well as potential biomarkers and drug targets or drug signatures in individual cancer patients. In this study, we applied this individualized bioinformatics approach to derive RCC specific gene signatures from patient samples and to identify, by C-MAP analysis of these gene signatures, candidate drugs that are anticipated to revert the ccRCC gene signature towards a healthy kidney gene expression profile (see flowchart of overall study design in Supplemental Figure   1 ). We clearly demonstrate that several FDA-approved drugs scoring high upon C-MAP analysis strongly induce apoptosis in RCC cell lines, and further enhance apoptosis when used in combinations. We, furthermore, show significant tumor inhibitory effects of pentamidine in a xenograft model of RCC. Overall, our data provide strong evidence for the potential of computationally repurposing FDA-approved drugs for the treatment of RCC. 
Microarray Data Deposition
All data sets have been deposited in the Gene Expression Omnibus, www.ncbi.nlm.nih.gov/geo (accession nos. GSE54709). despite the significant differences observed in input gene signatures used for every individual patient, indicating that these drugs may be the highest priority candidates to be evaluated for anti-cancer efficacy. Another set of drugs had enhanced negative enrichment in certain subsets of patients, potentially reflecting the different subtypes and different biological pathways affected in different patients. Furthermore, multiple drugs demonstrated more pronounced negative enrichment of <-0.7 only in some patients with a lot of variability from one patient to the other, and these drugs may be of less interest or may be useful only for a small subset of patients.
Pathway and Functional Enrichment
We selected the top scoring drugs (based on consistent reverse high scoring correlation across most or all ccRCC patients) with a negative enrichment correlation between -0.7 and -1.0 in more than 50% of all ccRCC patients ( and radiation treatment and are in clinical trials as cancer therapeutics (23) . PARP proteins have been associated with inflammation, neuronal death and ischemia, and novel phenanthridinone derivatives are potent and selective inhibitors of hepatitis C virus replication in vitro (24) . Oxaprozin is a propionic acid derivative widely used in the treatment of inflammatory and painful diseases of rheumatic and non-rheumatic basis (25) . Dopamine, a well-known neurotransmitter, plays a role in various physiological processes and, dopamine agonists are clinically being used to ameliorate pain (26) . Exemestane, a third-generation irreversible aromatase inhibitor with steroidal structure, has been used in the treatment of estrogen-receptor-positive breast cancer in postmenopausal women (27) .
High scoring candidate drugs from the Connectivity Map analysis induce apoptosis in RCC cell lines
Eight of the high scoring drugs for ccRCC were tested with regard to their effects on survival of the RCC cell lines ACHN and UOK, using as a starting point the same drug concentration as described in the C-MAP database for the breast and prostate cancer cell lines. Five drugs (pentamidine, oligomycin, oxaprozin, dopamine and exemestane) out of the eight evaluated drugs strongly induced apoptosis in both RCC cell lines (Figure 2A ), and two other drugs (yohimbine and phenanthridinone) also slightly induced apoptosis relative to the solvent DMSO (Figure 2A ) indicating that this set of structurally unrelated drugs elicits an apoptotic response in RCC cell lines. In contrast, the five drugs did not significantly impact cell survival of three non-cancerous cell lines, MS1, F12 and HEK 293 (Supplemental Figure 3) . Moreover, amitriptyline at 1 μM led to complete cell death of both RCC cell lines within 24 hours post treatment (data not shown). Additionally, we performed analysis of apoptosis induction by FACS. Using the same conditions we observed that combinatorial treatment induces a higher number of cells to apoptose and that this is a VHL dependent event (Supplemental Figure 7B) . 
Pentamidine inhibits in vivo RCC progression and increases survival rates in mice
Based on the above cell-based results we selected amitriptyline, oxaprozin and pentamidine for in vivo effects on RCC tumor growth. We utilized a xenograft model We tested the Pentamidine Gene Signature on our previously described (13) dataset of primary and metastatic ccRCC tumor samples and normal kidney controls to determine whether pentamidine counter-regulates genes deregulated in ccRCC patients.
Hierarchical clustering of these ccRCC and normal kidney samples using 83 genes ZEB1 is a key transcriptional regulator of epithelial-to-mesenchymal transition (EMT) (29) . High WNT1 expression correlates with increased tumor diameter, stage and vascular invasion (30) . RPS6KA1 is overexpressed in breast and prostate cancer and its inhibition in triple-negative breast cancers eliminates tumor-initiating cells (31) .
Overexpression of ITPKA in cancer increases migration and the metastatic potential of tumor cells (32) . These results indicate that pentamidine in fact induces a gene signature that is anticipated to reverse expression of a set of deregulated genes in ccRCC.
Functional and Pathway Enrichment analysis of pentamidine-regulated genes
To gain insight into the functional and biological pathways that are significantly affected by pentamidine altered genes, we performed functional and canonical pathway enrichment analysis using the Ingenuity pathway analysis software package (IPA 8.0).
The pentamidine upregulated genes are significantly linked to cellular/organ/tissue development, metabolism (e.g. amino acid, carbohydrate and lipid metabolism), cell cycle, cellular growth and proliferation (Supplemental Figure 9A) . Pentamidine 
Discussion
While advances in immunotherapy and anti-angiogenic therapy increase survival for patients with metastatic ccRCC, the vast majority of patients continue to succumb to the disease. Consequently, new therapeutic agents with enhanced efficacy against metastatic ccRCC are needed. Despite the continuous development of many new drugs targeting cancer, there is a large repertoire of FDA-approved drugs available that were not originally developed for cancer therapy, but may target biological pathways that are drivers of certain types of cancer. The systematic evaluation and screening of drugs for potential therapeutic efficacy against specific types of cancer has only recently become feasible upon the establishment of transcriptome signature databases for compendiums of small molecule drugs, such as the C-MAP database (15) .
In this study, we sought to identify new anti-ccRCC properties of FDA-approved drugs not currently used against ccRCC and repurpose such therapeutic compounds for 
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individual ccRCC patient to the healthy, baseline range of gene expression. This strategy enabled us to identify for each individual patient the set of genes in the tumor that are differentially expressed compared to healthy subjects. Despite a significant overlap of differentially expressed genes among all ccRCC patients, striking individual differences were also observed and hierarchical clustering indicated the potential existence of several different subtypes of ccRCC. Indeed, using completely different bioinformatics strategies, recent publications have identified several ccRCC subtypes (3, 4) . 
